Dr. Nitin Jain, MD
Claim this profileM D Anderson Cancer Center
Expert in Childhood Cancer
Expert in Lymphoma
16 reported clinical trials
24 drugs studied
Area of expertise
1Childhood Cancer
Global LeaderCD19 positive
Philadelphia chromosome positive
CD22 positive
2Lymphoma
Global LeaderCD19 positive
Philadelphia chromosome positive
CD22 positive
Affiliated Hospitals
M D Anderson Cancer Center
University Of Texas MD Anderson Cancer Center
Clinical Trials Nitin Jain, MD is currently running
Triple Therapy
for Chronic Lymphocytic Leukemia
This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab and obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, obinutuzumab, and venetoclax may work better in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or Richter syndrome.
Recruiting3 awards Phase 2
Venetoclax + Chemotherapy
for Leukemia
This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine
Recruiting3 awards Phase 1 & 2
More about Nitin Jain, MD
Clinical Trial Related7 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Nitin Jain, MD has experience with
- Venetoclax
- Ibrutinib
- Obinutuzumab
- Cyclophosphamide
- Pirtobrutinib
- Non-Operative
Breakdown of trials Nitin Jain, MD has run
Childhood Cancer
Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nitin Jain, MD specialize in?
Nitin Jain, MD focuses on Childhood Cancer and Lymphoma. In particular, much of their work with Childhood Cancer has involved CD19 positive patients, or patients who are Philadelphia chromosome positive.
Is Nitin Jain, MD currently recruiting for clinical trials?
Yes, Nitin Jain, MD is currently recruiting for 9 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Nitin Jain, MD has studied deeply?
Yes, Nitin Jain, MD has studied treatments such as Venetoclax, Ibrutinib, Obinutuzumab.
What is the best way to schedule an appointment with Nitin Jain, MD?
Apply for one of the trials that Nitin Jain, MD is conducting.
What is the office address of Nitin Jain, MD?
The office of Nitin Jain, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.